FDA Approval: MARIPOSA, First-Line Amivantamab plus Lazertinib for EGFR NSCLC
Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung can...
20 Aug 202428min
LCC In Mandarin
As part of IALC's ongoing series of podcasts in world languages, this podcast brings together four of the leading Chinese lung cancer experts who discuss current research and clinical issues, in Manda...
16 Aug 202440min
IASLC - WCLC 2024 Preview
Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Conference on Lung Cancer with the meeting’s other three...
13 Aug 202442min
IASLC - Spanish Episode Neoadjuvant Therapies In NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion in Spanish about perioperative chemotherapy and immunotherapy and how recent research may affect clinical deci...
9 Aug 202446min
Seminal Trial Series: Crizotinib in PROFILE 1001
Seminal Trial Series: Crizotinib in PROFILE 1001 by IASLC
6 Aug 202456min
Lung Cancer Considered in Farsi
Lung Cancer Considered in Farsi.
2 Aug 202454min
LCC In Greek
LCC In Greek by IASLC
26 Jul 20241h
IASLC - Immunotherapy In Driver - Positive NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patie...
26 Jul 202447min
